Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$1.27 - $3.18 $41,275 - $103,350
32,500 Added 204.62%
48,383 $119 Million
Q2 2023

Aug 11, 2023

BUY
$2.83 - $3.87 $44,948 - $61,467
15,883 New
15,883 $47.6 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $54.8M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Pale Fire Capital Se Portfolio

Follow Pale Fire Capital Se and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pale Fire Capital Se, based on Form 13F filings with the SEC.

News

Stay updated on Pale Fire Capital Se with notifications on news.